![]() “NMRA-266 entering phase 1 trials highlights the complementary relationship between university researchers and industry partners,” said Vice Provost for Research and Innovation Padma Raghavan. Moreover, this success is a testament to the virtue of academic drug discovery and Vanderbilt’s commitment to supporting the WCNDD, a clinical-stage biotech enterprise within the university.”įor the WCNDD to have such regular production of clinical assets when up against diverse neuroscience pipeline is unprecedented among academic drug discovery centers, according to Lindsley. “This mechanism and NMRA-266 represent a potential game-changer for schizophrenic patients and their families. Warren Foundation and pharmaceutical companies,” said Lindsley, also a University Professor of pharmacology, biochemistry and chemistry who holds the William K. “The M 4 PAM story has been a Homer-style Odyssey to get to this point and represents almost 20 years of research funded by National Institutes of Health, the William K. Overactive transmission of dopamine is connected to the positive, negative and cognitive symptoms of schizophrenia. In preclinical studies conducted by Conn and Lindsley, NMRA-266 was found to be highly selective to the M 4 receptor, the area of the brain that regulates neurotransmission of dopamine. Vanderbilt’s agreement with Neumora was centered around the M 4 muscarinic receptor, which NMRA-266 targets through positive allosteric modulation. Craig Lindsley (John Russell/Vanderbilt University) Vanderbilt and Neumora signed an exclusive, worldwide license and a research collaboration agreement for two novel series of M4 receptor modulator compounds, including NMRA-266, in February 2022. , a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments are developed. The clinical trial has been initiated by Neumora Therapeutics Inc. “Our work with Neumora is the very definition of translational research and the work we aim to do every day, which is applying innovation and discovery to help address the world’s most complex challenges.” “Vanderbilt is proud that a discovery by our researchers at the Warren Center is now a significant step closer to helping improve the lives of people with schizophrenia,” Chancellor Daniel Diermeier said. ![]() Jeffrey Conn, NMRA-266 has received Investigational New Drug clearance from the FDA. Developed in the labs of WCNDD Director Craig Lindsley and Director Emeritus P. The drug is an allosteric modulator that works through a mechanism that has been clinically validated in the treatment of disorders like schizophrenia. Food and Drug Administration for use in phase 1 clinical trials-the third WCNDD therapeutic to reach that benchmark. A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |